VD/VDR-vd-vdr.com

BRD4770 is a novel G9a(EHMT2) inhibitor with EC50 of 5 uM (trimethylated H3K9 in PANC-1 cell).

June 21, 2017

prudect name : BRD4770 is a novel G9a(EHMT2) inhibitor with EC50 of 5 uM (trimethylated H3K9 in PANC-1 cell).BRD4770 Synonyms: CAS NO: 1374601-40-7Molecular Formula: C25H23N3O3Molecular Weight: 413.47Purity: 98% minSolubility: DMSOStorage:…

📌

0💬 read more

prudect name : Beraprost sodiumSynonyms: CAS NO: 88475-69-8Molecular Formula: C24H29NaO5Molecular Weight: 420.47Purity: 99%Solubility: Storage: -20¡æ

prudect name : Beraprost sodium Synonyms: CAS NO: 88475-69-8Molecular Formula: C24H29NaO5Molecular Weight: 420.47Purity: 99%Solubility: Storage: -20¡æ Apalutamide References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18505544

📌

0💬 read more

(E)-5-(5-((3-(4-bromophenyl)-2-imino-4-oxothiazolidin-5-ylidene)methyl)furan-2-yl)isoindoline-1,3-dione

prudect name : (E)-5-(5-((3-(4-bromophenyl)-2-imino-4-oxothiazolidin-5-ylidene)methyl)furan-2-yl)isoindoline-1,3-dioneBioymifi Synonyms: CAS NO: 1420071-30-2Molecular Formula: C22H12BrN3O4SMolecular Weight: 493.0Purity: 98% minSolubility: in DMSOStorage: -20oC PA824 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18505499

📌

0💬 read more

Besifloxacin is a recently approved for the topical treatment of bacterial conjunctivitis fluoroquinolone drugs.

prudect name : Besifloxacin is a recently approved for the topical treatment of bacterial conjunctivitis fluoroquinolone drugs.Besifloxacin Synonyms: CAS NO: 141388-76-3Molecular Formula: C19H21ClFN3O3Molecular Weight: 393.84Purity: 99%Solubility: Storage: −20°C 2 years…

📌

0💬 read more

Bosutinib is a dual kinase inhibitor. With imatinib, bosutinib both Abl and inhibition of their own SRC kinase, thereby inhibiting cell growth and apoptosis (cell death)

prudect name : Bosutinib is a dual kinase inhibitor. With imatinib, bosutinib both Abl and inhibition of their own SRC kinase, thereby inhibiting cell growth and apoptosis (cell death)Bosutinib(SKI-606) Synonyms:…

📌

0💬 read more

Brigatinib is a highly potent and selective investigational ALK inhibitor with mean IC50 value £¼ 100 nM in Ba/F3 cells. IC50 value: £¼ 100 nM Target: pan-ALK in vitro: Brigatinib inhibits all 17 ALK mutants previously observed to confer resistance to Crizotinib, Ceritinib, and/or Alectinib. in vivo: Brigatinib uniquely maintains substantial activity against the highly recalcitrant G1202R mutant. Brigatinib has exhibited promising antitumor activity in patients with Crizotinib-resistant disease in an ongoing phase 1/2 clinical trial.

prudect name : Brigatinib is a highly potent and selective investigational ALK inhibitor with mean IC50 value £¼ 100 nM in Ba/F3 cells. IC50 value: £¼ 100 nM Target: pan-ALK…

📌

0💬 read more

BIBW2992 (Afatinib) is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2. In cell-free in vitro kinase assays, BIBW2992 shows potent activity against wild-type and mutant forms of EGFR and HER2, similar to gefitinib in potency for L858R EGFR, but about 100-fold more active against the gefitinib resistant L858R-T790M EGFR double mutant, with an IC50 of 10 nM. BIBW2992 was effective in inhibiting survival of lung cancer cell lines harboring wild-type (H1666) or L858R/T790M (NCI-H1975) EGFR, with IC50s below 100 nM for these isoforms resistant to first-generation inhibitors anda subnanomolar IC50 for the gefitinibsensitive L858R expressedby H3255. Assessed in a standard xenograft model of the epidermoid carcinoma cell line A431. Daily oral treatment with BIBW2992 at 20 mg/kg for 25 days resulted in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%.

prudect name : BIBW2992 (Afatinib) is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2. In cell-free in vitro kinase assays, BIBW2992 shows…

📌

0💬 read more

BRD73954 ia a potent and selective HDAC inhibitor with IC50 of 36 nM and 120 nM for HDAC6 and HDAC8, respectively.

prudect name : BRD73954 ia a potent and selective HDAC inhibitor with IC50 of 36 nM and 120 nM for HDAC6 and HDAC8, respectively.BRD73954 Synonyms: CAS NO: 1440209-96-0Molecular Formula: C16H16N2O3Molecular…

📌

0💬 read more

Betamustine acts as an alkylating agent causing intra-strand and inter-strand cross-links between DNA bases. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism. Accordingly, this agent may be more efficacious and less susceptible to drug resistance than other alkylators.

prudect name : Betamustine acts as an alkylating agent causing intra-strand and inter-strand cross-links between DNA bases. Bendamustine may differ from other alkylators in that it may be more potent…

📌

0💬 read more

prudect name : BMS-791325;BeclabuvirSynonyms: CAS NO: 958002-33-0 958002-36-3 (hydrochloride)Molecular Formula: C36H45N5O5SMolecular Weight: 659.838Purity: 98% minSolubility:

prudect name : BMS-791325;Beclabuvir Synonyms: CAS NO: 958002-33-0 958002-36-3 (hydrochloride)Molecular Formula: C36H45N5O5SMolecular Weight: 659.838Purity: 98% minSolubility: in DMSOStorage: -20oC Daporinad References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18505320

📌

0💬 read more